437
Participants
Start Date
January 31, 2018
Primary Completion Date
January 24, 2019
Study Completion Date
January 24, 2019
RELVAR/BREO
RELVAR/BREO will be available at doses of 100/25 micrograms (µg) and 200/25 µg to be administered via ELLIPTA DPI. Subjects will be administered one inhalation of RELVAR/BREO once daily.
Salbutamol
Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
Smart phone app
Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.
HCP Dashboard
The information from sensors will be reviewed by the HCP via an online dashboard.
Sensors
Clip-on sensors will be fitted to electronically record the actuation data.
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, A Coruña
GSK Investigational Site, Rüdersdorf
GSK Investigational Site, Peralada( Girona)
GSK Investigational Site, Loja/ Granada
GSK Investigational Site, Richmond
GSK Investigational Site, Lübeck
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Charlotte
GSK Investigational Site, Pordenone
GSK Investigational Site, Miami
GSK Investigational Site, Aventura
GSK Investigational Site, Warendorf
GSK Investigational Site, Greenfield
GSK Investigational Site, Pisa
GSK Investigational Site, Glenview
GSK Investigational Site, Flossmoor
GSK Investigational Site, Hazelwood
GSK Investigational Site, Darmstadt
GSK Investigational Site, Oklahoma City
GSK Investigational Site, San Antonio
GSK Investigational Site, Napoli
GSK Investigational Site, Salerno
GSK Investigational Site, Palermo
GSK Investigational Site, Medford
GSK Investigational Site, Kelowna
GSK Investigational Site, Vancouver
GSK Investigational Site, Ajax
GSK Investigational Site, Burlington
GSK Investigational Site, London
GSK Investigational Site, Sarnia
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Toronto
GSK Investigational Site, Windsor
GSK Investigational Site, Montreal
GSK Investigational Site, Québec
GSK Investigational Site, Québec
GSK Investigational Site, Québec
GSK Investigational Site, Sherbrooke
GSK Investigational Site, Victoriaville
GSK Investigational Site, Leipzig
GSK Investigational Site, Leipzig
GSK Investigational Site, Breda
GSK Investigational Site, Groningen
GSK Investigational Site, Hengelo
GSK Investigational Site, Hoorn
GSK Investigational Site, The Hague
GSK Investigational Site, Zutphen
GSK Investigational Site, Balenyà (Barcelona)
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, La Roca Del Valles (Barcelona)
GSK Investigational Site, Aylesbury
GSK Investigational Site, Wigan
GSK Investigational Site, Wellingborough
GSK Investigational Site, Addlestone
GSK Investigational Site, Rotherham
GSK Investigational Site, Bristol
GSK Investigational Site, Chelmsford
GSK Investigational Site, Chertsey, Surrey
GSK Investigational Site, Harrogate
Lead Sponsor
GlaxoSmithKline
INDUSTRY